Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $9.5 million.

  • Beam Therapeutics' Accounts Payables rose 15039.35% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 15039.35%. This contributed to the annual value of $3.9 million for FY2024, which is 13939.39% up from last year.
  • As of Q3 2025, Beam Therapeutics' Accounts Payables stood at $9.5 million, which was up 15039.35% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Accounts Payables ranged from a high of $14.1 million in Q1 2023 and a low of $1.6 million during Q4 2023
  • Over the past 5 years, Beam Therapeutics' median Accounts Payables value was $7.1 million (recorded in 2022), while the average stood at $6.8 million.
  • As far as peak fluctuations go, Beam Therapeutics' Accounts Payables tumbled by 8209.1% in 2023, and later surged by 17594.98% in 2025.
  • Over the past 5 years, Beam Therapeutics' Accounts Payables (Quarter) stood at $7.5 million in 2021, then grew by 20.81% to $9.0 million in 2022, then crashed by 82.09% to $1.6 million in 2023, then skyrocketed by 139.39% to $3.9 million in 2024, then soared by 146.58% to $9.5 million in 2025.
  • Its Accounts Payables stands at $9.5 million for Q3 2025, versus $10.6 million for Q2 2025 and $7.7 million for Q1 2025.